Idiopathic pulmonary fibrosis
|Idiopathic pulmonary fibrosis|
|Other names: Cryptogenic fibrosing alveolitis, diffuse fibrosing alveolitis, usual interstitial pneumonitis|
|Figure A shows the location of the lungs and airways in the body. The inset image shows a detailed view of the lung's airways and air sacs in cross-section. |
Figure B shows fibrosis (scarring) in the lungs. The inset image shows a detailed view of the fibrosis and how it damages the airways and air sacs.
|Symptoms||Shortness of breath, dry cough|
|Complications||Pulmonary hypertension, heart failure, pneumonia, pulmonary embolism|
|Risk factors||Cigarette smoking, certain viral infections, family history|
|Diagnostic method||CT scan, lung biopsy|
|Differential diagnosis||Sarcoidosis, other interstitial lung diseases, hypersensitivity pneumonitis|
|Treatment||Pulmonary rehabilitation, supplemental oxygen, lung transplantation|
|Prognosis||Life expectancy ~ 4 years|
|Frequency||12 per 100,000 people per year|
Idiopathic pulmonary fibrosis (IPF) is a type of chronic scarring lung disease characterized by a progressive and irreversible decline in lung function. Symptoms typically include gradual onset of shortness of breath and a dry cough. Other changes may include feeling tired, and abnormally large and dome shaped finger and toenails (nail clubbing). Complications may include pulmonary hypertension, heart failure, pneumonia, or pulmonary embolism.
The cause is unknown. Risk factors include cigarette smoking, certain viral infections, and a family history of the condition. The underlying mechanism involves scarring of the lungs. Diagnosis requires ruling out other potential causes. It may be supported by a CT scan or lung biopsy which show usual interstitial pneumonia (UIP). It is a type of interstitial lung disease (ILD).
People often benefit from pulmonary rehabilitation and supplemental oxygen. Certain medications like pirfenidone or nintedanib may slow the progression of the disease. Lung transplantation may also be an option.
About 5 million people are affected globally. The disease newly occurs in about 12 per 100,000 people per year. Those in their 60s and 70s are most commonly affected. Males are affected more often than females. Average life expectancy following diagnosis is about four years.
Signs and symptoms
In many people, symptoms are present for a considerable time before diagnosis. The most common clinical features of IPF include the following:
- Age over 50 years
- Dry, non-productive cough on exertion
- Progressive exertional dyspnea (shortness of breath with exercise)
- Dry, inspiratory bibasilar "velcro-like" crackles on auscultation (a crackling sound in the lungs during inhalation similar to Velcro being torn apart slowly, heard with a stethoscope).
- Clubbing of the digits, a disfigurement of the finger tips or toes (see image)
- Abnormal pulmonary function test results, with evidence of restriction and impaired gas exchange.
Some of these features are due to chronic hypoxemia (oxygen deficiency in the blood), are not specific for IPF, and can occur in other pulmonary disorders. IPF should be considered in all patients with unexplained chronic exertional dyspnea who present with cough, inspiratory bibasilar crackles, or finger clubbing.
Assessment of "velcro" crackles on lung auscultation is a practical way to improve the earlier diagnosis of IPF. Fine crackles are easily recognized by clinicians and are characteristic of IPF.
If bilateral fine crackles are present throughout the inspiratory time and are persisting after several deep breaths, and if remaining present on several occasions several weeks apart in a subject aged ≥60 years, this should raise the suspicion of IPF and lead to consideration of an HRCT scan of the chest which is more sensitive than a chest X-ray. As crackles are not specific for IPF, they must prompt a thorough diagnostic process.
The cause of IPF is unknown but certain environmental factors and exposures have been shown to increase the risk of getting IPF. Cigarette smoking is the best recognized and most accepted risk factor for IPF, and increases the risk of IPF by about twofold. Other environmental and occupation exposures such as exposure to metal dust, wood dust, coal dust, silica, stone dust, biologic dusts coming from hay dust or mold spores or other agricultural products, and occupations related to farming/livestock have also been shown to increase the risk for IPF. There is some evidence that viral infections may be associated with idiopathic pulmonary fibrosis and other fibrotic lung diseases.
Despite extensive investigation, the cause of IPF remains unknown. The fibrosis in IPF has been linked to cigarette smoking, environmental factors (e.g. occupational exposure to gases, smoke, chemicals or dusts), other medical conditions including gastroesophageal reflux disease (GERD), or to genetic predisposition (familial IPF). However, none of these is present in all people with IPF and therefore do not provide a completely satisfactory explanation for the disease.
IPF is believed to be the result of an aberrant wound healing process including/involving abnormal and excessive deposition of collagen (fibrosis) in the pulmonary interstitium with minimal associated inflammation.
It is hypothesized that the initial or repetitive injury in IPF occurs to the lung cells, called alveolar epithelial cells (AECs, pneumocytes), which line the majority of the alveolar surface. When type I AECs are damaged or lost, it is thought that type II AECs undergo proliferation to cover the exposed basement membranes. In normal repair, the hyperplastic type II AECs die and the remaining cells spread and undergo a differentiation process to become type I AECs. Under pathologic conditions and in the presence of transforming growth factor beta (TGF-β), fibroblasts accumulate in these areas of damage and differentiate into myofibroblasts that secrete collagen and other proteins. In the past, it was thought that inflammation was the first event in initiating lung tissue scarring. Later findings showed that the development of fibroblastic foci precedes the accumulation of inflammatory cells and the consequent deposition of collagen. This pathogenetic model is indirectly supported by the clinical features of IPF, including an insidious onset over several years, relatively infrequent acute exacerbations, and failure to respond to immunosuppressive therapy. A number of therapies that target fibroblast activation or the synthesis of extracellular matrix are currently in early testing or are being considered for development.
Familial IPF accounts for less than 5% of the total of patients with IPF and is clinically and histologically indistinguishable from sporadic IPF. Genetic associations include mutations in pulmonary surfactant proteins A1, A2, C (SFTPA1, SFTPA2B) and mucin (MUC5B). A remarkable aspect of the MUC5B variant is its high frequency of detection, as it is found in approximately 20% of individuals with Northern and Western European ancestry and in 19% of the Framingham Heart Study population. Mutations in human telomerase genes are also associated with familial pulmonary fibrosis and in some patients with sporadic IPF (e.g. the TERT, TERC genes). Recently an X-linked mutation in a third telomerase-associated gene, dyskerin (DKC1), has been described in a family with IPF.[unreliable medical source?]
An earlier diagnosis of IPF is a prerequisite for earlier treatment and, potentially, improvement of the long-term clinical outcome of this progressive and ultimately fatal disease. If IPF is suspected, diagnosis can be challenging but a multidisciplinary approach involving a pulmonologist, radiologist and pathologist expert in interstitial lung disease has been shown to improve the accuracy of IPF diagnosis.
A Multidisciplinary Consensus Statement on the Idiopathic Interstitial Pneumonias published by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) in 2000 proposed specific major and minor criteria for establishing the diagnosis of IPF. However, in 2011, new simplified and updated criteria for the diagnosis and management of IPF were published by the ATS, ERS, together with the Japanese Respiratory Society (JRS) and Latin American Thoracic Association (ALAT). Currently, a diagnosis of IPF requires:
- Exclusion of known causes of ILD, e.g., domestic and occupational environmental exposures, connective tissue disorders, or drug exposure/toxicity
- The presence of a typical radiological pattern of usual interstitial pneumonia (UIP) on high-resolution computed tomography (HRCT).
In the right clinical setting, it is possible to make the diagnosis of IPF by HRCT alone, obviating the need for surgical lung biopsy.
Recognizing IPF in clinical practice can be challenging as symptoms often appear similar to those of more common diseases, such as asthma, chronic obstructive pulmonary disease (COPD) and congestive heart failure (www.diagnoseipf.com). The key issue facing clinicians is whether the presenting history, symptoms (or signs), radiology, and pulmonary function testing are collectively in keeping with the diagnosis of IPF or whether the findings are due to another process. It has long been recognized that patients with ILD related to asbestos exposure, drugs (such as chemotherapeutic agents or nitrofurantoin), rheumatoid arthritis and scleroderma/systemic sclerosis may be difficult to distinguish from IPF. Other differential diagnostic considerations include interstitial lung disease related to mixed connective tissue disease, advanced sarcoidosis, chronic hypersensitivity pneumonitis, pulmonary Langerhan's cell histiocytosis and radiation-induced lung injury.
Idiopathic pulmonary fibrosis (IPF) belongs to a large group of more than 200 lung diseases known as interstitial lung diseases (ILDs), which are characterized by the involvement of the lung interstitium, the tissue between the air sacs of the lung. IPF is one specific presentation of idiopathic interstitial pneumonia (IIP), which is in turn a type of ILD, also known as diffuse parenchymal lung disease (DPLD).
The 2002 American Thoracic Society/European Respiratory Society (ATS/ERS) classification of IIPs was updated in 2013. In this new classification there are three main categories of idiopathic interstitial pneumonias (IIPs): major IIPs, rare IIPs, and unclassifiable IIPs. The major IIPs are grouped into chronic fibrosing IPs (this includes IPF and non-specific interstitial pneumonia [NSIP]); smoking-related IPs (i.e. respiratory bronchiolitis–interstitial lung disease [RB-ILD] and desquamative interstitial pneumonia [DIP]); and acute/subacute IPs (i.e. cryptogenic organizing pneumonia [COP] and acute interstitial pneumonia [AIP]).
The diagnosis of IIPs requires exclusion of known causes of ILD. Examples of ILD of known cause include hypersensitivity pneumonitis, pulmonary Langerhan's cell histiocytosis, asbestosis, and collagen vascular disease. However, these disorders frequently affect not only the interstitium, but also the airspaces, peripheral airways, and blood vessels.
Chest X-rays are useful in the follow up routine of IPF patients. Plain chest X-rays are unfortunately not diagnostic but may reveal decreased lung volumes, typically with prominent reticular interstitial markings near the lung bases.
The radiological evaluation through HRCT is an essential point in the diagnostic pathway in IPF. HRCT is performed using a conventional computed axial tomographic scanner without injection of contrast agents. Evaluation slices are very thin, 1–2 mm.
Typical HRCT of the chest of IPF demonstrates fibrotic changes in both lungs, with a predilection for the bases and the periphery. According to the joint ATS/ERS/JRS/ALAT 2011 guidelines, HRCT is an essential component of the diagnostic pathway in IPF which can identify UIP by the presence of:
- Reticular opacities, often associated with traction bronchiectasis
- Honeycombing manifested as cluster cystic airspaces, typically of comparable diameters (3–10 mm) but occasionally large. Usually sub-pleural and characterized by well-defined walls and disposed in at least two lines. Generally one line of cysts is not sufficient to define honeycombing
- Ground-glass opacities are common but less extensive than the reticulation
- Distribution characteristically basal and peripheral though often patchy.
According to the updated 2011 guidelines, in the absence of a typical UIP pattern on HRCT, a surgical lung biopsy is required for confident diagnosis.
Histologic specimens for the diagnosis of IPF must be taken at least in three different places and be large enough that the pathologist can comment on the underlying lung architecture. Small biopsies, such as those obtained via transbronchial lung biopsy (performed during bronchoscopy) are usually not sufficient for this purpose. Hence, larger biopsies obtained surgically via a thoracotomy or thoracoscopy are usually necessary.
Lung tissue from people with IPF usually show a characteristic histopathologic UIP pattern and is therefore the pathologic counterpart of IPF. Although a pathologic diagnosis of UIP often corresponds to a clinical diagnosis of IPF, a UIP histologic pattern can be seen in other diseases as well, and fibrosis of known origin (rheumatic diseases for example). There are four key features of UIP including interstitial fibrosis in a 'patchwork pattern', interstitial scarring, honeycomb changes and fibroblast foci.
Fibroblastic foci are dense collections of myofibroblasts and scar tissue and, together with honeycombing, are the main pathological findings that allow a diagnosis of UIP.
Bronchoalveolar lavage (BAL) is a well-tolerated diagnostic procedure in ILD. BAL cytology analyses (differential cell counts) should be considered in the evaluation of patients with IPF at the discretion of the treating physician based on availability and experience at their institution. BAL may reveal alternative specific diagnoses: malignancy, infections, eosinophilic pneumonia, histiocytosis X, or alveolar proteinosis. In the evaluation of patients with suspected IPF, the most important application of BAL is in the exclusion of other diagnoses. Prominent lymphocytosis (>30%) generally allows excluding a diagnosis of IPF.
Pulmonary function tests
Spirometry classically reveals a reduction in the vital capacity (VC) with either a proportionate reduction in airflows, or increased airflows for the observed vital capacity. The latter finding reflects the increased lung stiffness (reduced lung compliance) associated with pulmonary fibrosis, which leads to increased lung elastic recoil.
Measurement of static lung volumes using body plethysmography or other techniques typically reveals reduced lung volumes (restriction). This reflects the difficulty encountered in inflating the fibrotic lungs.
The diffusing capacity for carbon monoxide (DLCO) is invariably reduced in IPF and may be the only abnormality in mild or early disease. Its impairment underlies the propensity of patients with IPF to exhibit oxygen desaturation with exercise which can also be evaluated using the 6-minute walk test (6MWT).
Terms such as 'mild', 'moderate', and 'severe' are sometimes used for staging disease and are commonly based on resting pulmonary function test measurements. However, there is no clear consensus regarding the staging of IPF patients and what are the best criteria and values to use. Mild-to-moderate IPF has been characterized by the following functional criteria:
- Forced vital capacity (FVC) of ≥50%
- DLCO of ≥30%
- 6MWT distance ≥150 meters.
The goals of treatment in IPF are essentially to reduce the symptoms, stop disease progression, prevent acute exacerbations, and prolong survival. Preventive care (e.g. vaccinations) and symptom-based treatment should be started early in every patient.
In the 2011 IPF guidelines, oxygen therapy, or supplementary oxygen for home use, became a strong recommendation for use in those patients with significantly low oxygen levels at rest. Although oxygen therapy has not been shown to improve survival in IPF, some data indicate an improvement in exercise capacity.
Fatigue and loss of muscular mass are common and disabling problems for patients with IPF. Pulmonary rehabilitation may alleviate the overt symptoms of IPF and improve functional status by stabilizing and/or reversing the extrapulmonary features of the disease. The number of published studies on the role of pulmonary rehabilitation in idiopathic pulmonary fibrosis is small, but most of these studies have found significant short-term improvements in functional exercise tolerance, quality of life, and dyspnea on exertion. Typical programs of rehabilitation include exercise training, nutritional modulation, occupational therapy, education and psychosocial counseling. In the late phase of disease, IPF patients tend to discontinue physical activity due to increasing dyspnea. Whenever possible, this should be discouraged.
A number of treatments have been investigated in the past for IPF, including interferon gamma-1β, bosentan, ambrisentan, and anticoagulants, but these are no longer considered effective treatment options. Many of these earlier studies were based on the hypothesis that IPF is an inflammatory disorder.
A Cochrane review comparing pirfenidone with placebo, found a reduced risk of disease progression by 30%. FVC or VC was also improved, even if a mild slowing in FVC decline could be demonstrated only in one of the two CAPACITY trials. A third study, which was completed in 2014 found reduced decline in lung function and IPF disease progression. The data from the ASCEND study were also pooled with data from the two CAPACITY studies in a pre-specified analysis which showed that pirfenidone reduced the risk of death by almost 50% over one year of treatment.
N-acetylcysteine and triple therapy
N-Acetylcysteine (NAC) is a precursor to glutathione, an antioxidant. It has been hypothesized that treatment with high doses of NAC may repair an oxidant–antioxidant imbalance that occurs in the lung tissue of patients with IPF. In the first clinical trial of 180 patients (IFIGENIA), NAC was shown in previous study to reduce the decline in VC and DLCO over 12 months of follow-up when used in combination with prednisone and azathioprine (triple therapy).
More recently, a large randomized, controlled trial (PANTHER-IPF) was undertaken by the National Institutes of Health (NIH) in the US to evaluate triple therapy and NAC monotherapy in IPF patients. This study found that the combination of prednisone, azathioprine, and NAC increased the risk of death and hospitalizations and the NIH announced in 2012 that the triple-therapy arm of the PANTHER-IPF study had been terminated early.
This study also evaluated NAC alone and the results for this arm of the study were published in May 2014 in the New England Journal of Medicine, concluding that "as compared with placebo, acetylcysteine offered no significant benefit with respect to the preservation of FVC in patients with idiopathic pulmonary fibrosis with mild-to-moderate impairment in lung function".
Nintedanib is a triple angiokinase inhibitor that targets receptor tyrosine kinases involved in the regulation of angiogenesis: fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), which have also been implicated in the pathogenesis of fibrosis and IPF. In both phase III trials, nintedanib reduced the decline in lung function by approximately 50% over one year. It was approved by the US FDA in October 2014 and authorised in Europe in January 2015.
Lung transplantation may be suitable for those patients physically eligible to undergo a major transplant operation. In IPF patients, lung transplant has been shown to reduce the risk of death by 75% as compared with patients who remain on the waiting list. Since the introduction of the lung allocation score (LAS), which prioritizes transplant candidates based on survival probability, IPF has become the most common indication for lung transplantation in the USA.
Symptomatic patients with IPF younger than 65 years of age and with a body mass index (BMI) ≤26 kg/m2 should be referred for lung transplantation, but there are no clear data to guide the precise timing for LTx. Although controversial, the most recent data suggest that bilateral lung transplantation is superior to single lung transplantation in patients with IPF. Five-year survival rates after lung transplantation in IPF are estimated at between 50 and 56%.
Palliative care focuses on reducing symptoms and improving the comfort of patients rather than treating the disease. This may include treatment of worsening symptoms with the use of chronic opioids for severe dyspnea and cough. Further, oxygen therapy may be useful for palliation of dyspnea in hypoxemic patients.
Palliative care also includes relief of physical and emotional suffering and psychosocial support for patients and caregivers. With disease progression, patients may experience fear, anxiety and depression and psychological counseling should therefore be considered. In a recent study of outpatients with ILDs, including IPF, depression score, functional status (as assessed by walk test), as well as pulmonary function, all contributed to the severity of dyspnea.
In selected cases of particularly severe dyspnea morphine could be considered. It can reduce dyspnea, anxiety and cough without significant decrease in oxygen saturation.
IPF is often misdiagnosed, at least until physiological and/or imaging data suggest the presence of an ILD leading to delay in accessing appropriate care. Considering that IPF is a disease with a median survival of three years after diagnosis, early referral to a center with specific expertise should therefore be considered for any patient with suspected or known ILD. On the basis of the complex differential diagnostic, multidisciplinary discussion between pulmonologists, radiologists, and pathologists experienced in the diagnosis of ILD is of the utmost importance to an accurate diagnosis.
After diagnosis of IPF, and the appropriate treatment choice according to symptoms and stage of disease, a close follow-up should be applied. Due to the high variable course of disease, the higher incidence of complications such as lung cancer (up to 25% of patients has been reported in IPF) a routine evaluation every 3 to 6 months, including spirometry (body plethysmography), diffusion capacity testing, chest X-rays, 6MWT, assessment of dyspnea, quality of life, oxygen requirement is mandatory.
In addition, the increasing awareness of complications and common concomitant conditions frequently associated with IPF requires a routinely evaluation of comorbidities, most of them simply reflecting concurrent diseases of aging, and medications with their interaction and side effects.
Acute exacerbations of IPF (AE-IPF) are defined as an unexplained worsening or development of dyspnea within 30 days with new radiological infiltrates at HRCT abnormality often superimposed on a background consistent with UIP pattern. The yearly incidence of AE-IPF is between 10 and 15% of all patients. The prognosis of AE-IPF is poor, with mortality ranging from 78% to 96%. Other causes of AE-IPF such as pulmonary embolism, congestive heart failure, pneumothorax, or infection need to be excluded. Pulmonary infection have to be ruled out by endotracheal aspirate or BAL.
Many patients experiencing acute deterioration require intensive care treatment, particularly when respiratory failure is associated with hemodynamic instability, significant comorbidities or severe hypoxemia. However, mortality during hospitalization is high. Mechanical ventilation should be introduced only after carefully weighing the person's long-term prognosis and, whenever possible, the person's wishes. However, current guidelines discourage the use of mechanical ventilation in patients with respiratory failure secondary to IPF.
The clinical course of IPF can be unpredictable. IPF progression is associated with an estimated median survival time of 2 to 5 years following diagnosis. The 5-year survival for IPF ranges between 20–40%, a mortality rate higher than that of a number of malignancies, including colon cancer, multiple myeloma and bladder cancer.
Recently a multidimensional index and staging system has been proposed to predict mortality in IPF. The name of the index is GAP and is based on gender [G], age [A], and two lung physiology variables [P] (FVC and DLCO that are commonly measured in clinical practice to predict mortality in IPF. The highest stage of GAP (stage III) has been found to be associated with a 39% risk of mortality at 1 year. This model has also been evaluated in IPF and other ILDs and shown good performance in predicting mortality in all main ILD subtypes. A modified ILD-GAP Index has been developed for application across ILD subtypes to provide disease-specific survival estimates. In IPF patients, the overall mortality at 5 years rate is high but the annual rate of all-cause mortality in patients with mild to moderate lung impairment is relatively low. This is the reason why change in lung function (FVC) is usually measured in 1-year clinical trials of IPF treatments rather than survival.
In addition to clinical and physiological parameters to predict how rapidly patients with IPF might progress, genetic and molecular features are also associated with IPF mortality. For example, it has been shown that IPF patients who have a specific genotype in the mucin MUC5B gene polymorphism (see above) experience slower decline in FVC and significantly improved survival. Even if such data are interesting from a scientific point of view, the application in the clinical routine of a prognostic model based on specific genotypes is still not possible.
Although rare, IPF is the most common form of IIP. The prevalence of IPF has been estimated between 14.0 and 42.7 per 100,000 persons based on a USA analysis of healthcare claims data, with variation depending on the case definitions used in this analyses. IPF is more common in men than in women and is usually diagnosed in people over 50 years of age.
The incidence of IPF is difficult to determine as uniform diagnostic criteria have not been applied consistently. A recent study from the USA estimated the incidence of IPF to be between 6.8 and 16.3 per 100,000 persons. In the 27 European Union countries, a range of sources estimate an incidence of 4.6–7.4 people per 100,000 of the population, suggesting that approximately 30,000–35,000 new patients will be diagnosed with IPF each year.
A recent single-centre, retrospective, observational cohort study including incident patients diagnosed with ILD at Aarhus University Hospital (Denmark) between 2003 and 2009 revealed an incidence of 4.1 per 100,000 inhabitants/year for ILD. IPF was the most common diagnosis (28%) followed by connective tissue disease-related ILD (14%), hypersensitivity pneumonitis (7%) and non-specific interstitial pneumonia (NSIP) (7%). IPF incidence was 1.3 per 100,000 inhabitants/year.
Due to a heterogeneous distribution of the disease across European countries, epidemiological data needs to be updated through a Europe-wide registry for ILD and IPF.
IPF has been recognized in several breeds of both dogs and cats, and has been best characterized in West Highland White Terriers. Veterinary patients with the condition share many of the same clinical signs as their human counterparts, including progressive exercise intolerance, increased respiratory rate, and eventual respiratory distress. Prognosis is generally poor.
A number of agents are currently being investigated in Phase II clinical trials for IPF, including the monoclonal antibodies simtuzumab, tralokinumab, lebrikizumab and FG-3019, a lysophosphatidic acid receptor antagonist (BMS-986020). A Phase II study of STX-100 is also ongoing. These molecules are directed against several growth factors and cytokines that are known to play a role in the proliferation, activation, differentiation or inappropriate survival of fibroblasts.
mir-29 microRNA precursor investigations in mice have produced reversal of induced IPF. MRG-201 is currently being tested as-of 2016, but not in IPF patients yet, and no human trials for IPF use have been scheduled as of January 2016[update].
Stem cell therapies for IPF are an area of research.
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 "Idiopathic Pulmonary Fibrosis". NHLBI. Archived from the original on 9 July 2021. Retrieved 21 January 2018.
- ↑ 2.0 2.1 2.2 2.3 Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. (July 2015). "An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline". American Journal of Respiratory and Critical Care Medicine. 192 (2): e3–19. doi:10.1164/rccm.201506-1063ST. PMID 26177183.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 3.26 3.27 3.28 3.29 3.30 3.31 3.32 3.33 3.34 Raghu G, Collard HR, Egan JJ, et al. (2011). "An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management". American Journal of Respiratory and Critical Care Medicine. 183 (6): 788–824. doi:10.1164/rccm.2009-040GL. PMC 5450933. PMID 21471066.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Ferri, Fred F. (2017). Ferri's Clinical Advisor 2018 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 691. ISBN 9780323529570. Archived from the original on 2018-01-22. Retrieved 2018-01-22.
- ↑ 5.0 5.1 Meltzer EB, Noble PW (2008). "Idiopathic pulmonary fibrosis". Orphanet Journal of Rare Diseases. 3 (1): 8. doi:10.1186/1750-1172-3-8. PMC 2330030. PMID 18366757.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. (September 2013). "An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias". American Journal of Respiratory and Critical Care Medicine. 188 (6): 733–48. doi:10.1164/rccm.201308-1483ST. PMC 5803655. PMID 24032382.
- ↑ 7.0 7.1 Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, et al. (2007). "Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia". American Journal of Respiratory and Critical Care Medicine. 168 (5): 543–548. CiteSeerX 10.1.1.320.6411. doi:10.1164/rccm.200209-1112OC. PMID 12773329.
- ↑ 8.0 8.1 8.2 Raghu G, Weycker D, Edesberg J, Bradford WZ, Oster G (2006). "Incidence and prevalence of idiopathic pulmonary fibrosis". American Journal of Respiratory and Critical Care Medicine. 174 (7): 810–816. doi:10.1164/rccm.200602-163oc. PMID 16809633.
- ↑ 9.0 9.1 Cottin V, Cordier JF (2012). "Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis". European Respiratory Journal. 40 (3): 519–521. doi:10.1183/09031936.00001612. PMID 22941541.
- ↑ Baughman RP, Shipley RT, Loudon RG, Lower EE (1991). "Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis". Chest. 100 (1): 96–101. doi:10.1378/chest.100.1.96. PMID 2060395.
- ↑ 11.0 11.1 11.2 Olson AL, Swigris JJ (Mar 2012). "Idiopathic pulmonary fibrosis: diagnosis and epidemiology". Clinics in Chest Medicine. 33 (1): 41–50. doi:10.1016/j.ccm.2011.12.001. PMID 22365244.
- ↑ Williams, KJ (March 2014). "Gammaherpesviruses and Pulmonary Fibrosis: Evidence From Humans, Horses, and Rodents". Veterinary Pathology. 51 (2): 372–384. doi:10.1177/0300985814521838. PMID 24569614.
- ↑ García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, et al. (December 2011). "Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis". Respiratory Medicine. 105 (12): 1902–7. doi:10.1016/j.rmed.2011.08.022. PMID 21917441.[unreliable medical source?]
- ↑ 14.0 14.1 Harari S, Caminati A (2010). "IPF: new insight on pathogenesis and treatment". Allergy. 65 (5): 537–553. doi:10.1111/j.1398-9995.2009.02305.x. PMID 20121758.
- ↑ 15.0 15.1 Loomis-King H, Flaherty KR, Moore BB (April 2013). "Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis". Current Opinion in Pharmacology. 13 (3): 377–385. doi:10.1016/j.coph.2013.03.015. PMC 3686907. PMID 23602652.
- ↑ Pardo A, Selman M (2002). "Idiopathic pulmonary fibrosis: new insights in its pathogenesis". The International Journal of Biochemistry & Cell Biology. 34 (12): 1534–1538. doi:10.1016/s1357-2725(02)00091-2. PMID 12379275.
- ↑ Selman M, King TE, Pardo A (2001). "Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy". Annals of Internal Medicine. 134 (2): 136–151. doi:10.7326/0003-4819-134-2-200101160-00015. PMID 11177318.
- ↑ 18.0 18.1 "OMIM Entry - # 178500 - PULMONARY FIBROSIS, IDIOPATHIC; IPF". Omim.org. Archived from the original on 8 August 2015. Retrieved 7 June 2018.
- ↑ Mathai S, et al. (2014). "Genetic susceptibility and pulmonary fibrosis". Current Opinion in Pulmonary Medicine. 20 (5): 429–435. doi:10.1097/MCP.0000000000000074. PMC 4337021. PMID 25022318.
- ↑ Kropski JA, Mitchell DB, Markin C, et al. (Feb 6, 2014). "A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia". Chest. 146 (1): e1–7. doi:10.1378/chest.13-2224. PMC 4077414. PMID 24504062.
- ↑ Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, et al. (2004). "Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?". American Journal of Respiratory and Critical Care Medicine. 170 (8): 904–910. doi:10.1164/rccm.200402-147OC. PMID 15256390.
- ↑ Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, et al. (2007). "Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?". American Journal of Respiratory and Critical Care Medicine. 175 (10): 1054–1060. doi:10.1164/rccm.200606-833OC. PMC 1899268. PMID 17255566.
- ↑ Ohshimo S, Bonella F, Cui A, Beume M, Kohno N, Guzman J, Costabel U (2009). "Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis". American Journal of Respiratory and Critical Care Medicine. 179 (11): 1043–1047. doi:10.1164/rccm.200808-1313oc. PMID 19246718.
- ↑ Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, et al. (2005). "Interpretative strategies for lung function tests". European Respiratory Journal. 26 (5): 948–968. doi:10.1183/09031936.05.00035205. PMID 16264058.
- ↑ 25.0 25.1 Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, et al. (2011). "Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials". The Lancet. 377 (9779): 1760–1769. doi:10.1016/S0140-6736(11)60405-4. PMID 21571362.
- ↑ Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK (June 2005). "The clinical course of patients with idiopathic pulmonary fibrosis". Annals of Internal Medicine. 142 (12 Pt 1): 963–7. doi:10.7326/0003-4819-142-12_part_1-200506210-00005. PMID 15968010.
- ↑ 27.0 27.1 27.2 King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. (May 2014). "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis" (PDF). New England Journal of Medicine. 370 (22): 2083–92. doi:10.1056/NEJMoa1402582. PMID 24836312. Archived (PDF) from the original on 2021-12-19. Retrieved 2019-07-05.
- ↑ 28.0 28.1 Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. (May 2014). "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis" (PDF). New England Journal of Medicine. 370 (22): 2071–82. doi:10.1056/NEJMoa1402584. hdl:11365/974374. PMID 24836310. Archived (PDF) from the original on 2021-08-28. Retrieved 2019-08-08.
- ↑ Lee JS, McLaughlin S, Collard HR (2011). "Comprehensive care of the patient with idiopathic pulmonary fibrosis". Current Opinion in Pulmonary Medicine. 17 (5): 348–354. doi:10.1097/mcp.0b013e328349721b. PMID 21760508.
- ↑ Morrison DA, Stovall JR (1992). "Increased exercise capacity in hypoxemic patients after long-term oxygen therapy". Chest. 102 (2): 542–550. doi:10.1378/chest.102.2.542. PMID 1643945.
- ↑ 31.0 31.1 31.2 Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, Richeldi L (2012). "Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges". Multidisciplinary Respiratory Medicine. 7 (1): 42. doi:10.1186/2049-6958-7-42. PMC 3537555. PMID 23146172.
- ↑ Lee JS, McLaughlin S, Collard HR (September 2011). "Comprehensive care of the patient with idiopathic pulmonary fibrosis". Current Opinion in Pulmonary Medicine. 17 (5): 348–54. doi:10.1097/mcp.0b013e328349721b. PMID 21760508.
- ↑ Kenn K, Gloeckl R, Behr J (2013). "Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis--a review". Respiration; International Review of Thoracic Diseases. 86 (2): 89–99. doi:10.1159/000354112. PMID 23942353.
- ↑ King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. (July 2009). "Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial". Lancet. 374 (9685): 222–8. doi:10.1016/S0140-6736(09)60551-1. PMID 19570573.
- ↑ King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. (July 2011). "BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis". American Journal of Respiratory and Critical Care Medicine. 184 (1): 92–9. doi:10.1164/rccm.201011-1874OC. PMID 21474646.
- ↑ Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. (May 2013). "Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial". Annals of Internal Medicine. 158 (9): 641–9. doi:10.7326/0003-4819-158-9-201305070-00003. PMID 23648946.
- ↑ Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al. (July 2012). "A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis". American Journal of Respiratory and Critical Care Medicine. 186 (1): 88–95. doi:10.1164/rccm.201202-0314OC. PMC 3400994. PMID 22561965.
- ↑ Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L (2010). "Non-steroid agents for idiopathic pulmonary fibrosis". Cochrane Database of Systematic Reviews (9): CD003134–non disponibile. doi:10.1002/14651858.CD003134.pub2. hdl:11380/680648. PMID 20824834.
- ↑ Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al. (2005). "High-dose acetylcysteine in idiopathic pulmonary fibrosis" (PDF). New England Journal of Medicine. 353 (21): 2229–2242. doi:10.1056/NEJMoa042976. hdl:2066/47718. PMID 16306520. Archived (PDF) from the original on 2019-02-19. Retrieved 2019-07-05.
- ↑ Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ (May 2012). "Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis". New England Journal of Medicine. 366 (21): 1968–77. doi:10.1056/NEJMoa1113354. PMC 3422642. PMID 22607134.
- ↑ "Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful". NIH. October 21, 2011. Archived from the original on 2021-05-08. Retrieved 2013-04-11.
- ↑ The Idiopathic Pulmonary Fibrosis Clinical Research Network. (2014). "Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis". New England Journal of Medicine. 370 (22): 2093–2102. doi:10.1056/nejmoa1401739. PMC 4116664. PMID 24836309.
- ↑ "BIBF 1120 Fact Sheet" (PDF). Dl.groovygecko.net. Archived (PDF) from the original on 2016-03-03. Retrieved 2014-04-08.
- ↑ "FDA Approval Package for Nintedanib" (PDF). www.accessdata.fda.gov. Archived (PDF) from the original on 2020-08-01. Retrieved 2019-01-07.
- ↑ "Ofev | European Medicines Agency". www.ema.europa.eu. 2018-09-17. Archived from the original on 2018-12-24. Retrieved 2019-01-07.
- ↑ Russo MJ, Iribarne A, Hong KN, Davies RR, Xydas S, Takayama H, Ibrahimiye A, Gelijns AC, Bacchetta MD, D'Ovidio F, Arcasoy S, Sonett JR (2010). "High lung allocation score is associated with increased morbidity and mortality following transplantation". Chest. 137 (3): 651–657. doi:10.1378/chest.09-0319. PMC 2832864. PMID 19820072.
- ↑ George TJ, Arnaoutakis GJ, Shah AS (2007). "Lung transplantation for idiopathic pulmonary fibrosis". The Annals of Thoracic Surgery. 84 (4): 1121–1128. doi:10.1016/j.athoracsur.2007.04.096. PMID 17888957.
- ↑ Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, Mehta AC, Minai OA, et al. (2011). "Lung transplant in idiopathic pulmonary fibrosis". Archives of Surgery. 146 (10): 1204–1209. doi:10.1001/archsurg.2011.239. PMID 22006881.
- ↑ Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell G (2009). "Lung transplantation in pulmonary fibrosis challenging early outcomes counter balanced by surprisingly good outcomes beyond 15 years". Transplantation Proceedings. 41 (1): 289–291. doi:10.1016/j.transproceed.2008.10.042. PMID 19249537.
- ↑ Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR (2011). "Depression and functional status are strongly associated with dyspnea in interstitial lung disease" (PDF). Chest. 139 (3): 609–616. doi:10.1378/chest.10-0608. PMID 20688924. Archived from the original (PDF) on 2020-08-01. Retrieved 2020-04-18.
- ↑ Allen S, Raut S, Woollard J, Vassallo M (2005). "Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis". Palliative Medicine. 19 (2): 128–130. doi:10.1191/0269216305pm998oa. PMID 15810751.
- ↑ 52.0 52.1 Agarwal R, Jindal SK (2008). "Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review". European Journal of Internal Medicine. 19 (4): 227–235. doi:10.1016/j.ejim.2007.04.024. PMID 18471669.
- ↑ Stern JB, Mal H, Groussard O, Brugière O, Marceau A, Jebrak G, Fournier M (2001). "Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure". Chest. 120 (1): 213–219. doi:10.1378/chest.120.1.213. PMID 11451841.
- ↑ 54.0 54.1 54.2 Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998). "Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis" (PDF). American Journal of Respiratory and Critical Care Medicine. 157 (1): 199–203. doi:10.1164/ajrccm.157.1.9704130. PMID 9445300. Archived from the original (PDF) on 2019-02-27. Retrieved 2019-12-30.
- ↑ 55.0 55.1 55.2 Kim DS, Collard HR, King TE (June 2006). "Classification and natural history of the idiopathic interstitial pneumonias". Proceedings of the American Thoracic Society. 3 (4): 285–92. doi:10.1513/pats.200601-005TK. PMC 2658683. PMID 16738191.
- ↑ 56.0 56.1 Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012). "A multidimensional index and staging system for idiopathic pulmonary fibrosis". Annals of Internal Medicine. 156 (10): 684–691. CiteSeerX 10.1.1.691.4472. doi:10.7326/0003-4819-156-10-201205150-00004. PMID 22586007.
- ↑ Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, et al. (2014). "Predicting Survival Across Chronic Interstitial Lung Disease: The ILD-GAP Model". Chest. 145 (4): 723–728. doi:10.1378/chest.13-1474. PMID 24114524.
- ↑ King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW (April 2014). "All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials". American Journal of Respiratory and Critical Care Medicine. 189 (7): 825–31. doi:10.1164/rccm.201311-1951OC. hdl:2318/156709. PMID 24476390.
- ↑ Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, et al. (2013). "Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis". JAMA. 309 (21): 2232–2239. doi:10.1001/jama.2013.5827. PMC 4545271. PMID 23695349.
- ↑ Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, et al. (2013). "Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis". Thorax. 68 (5): 436–441. doi:10.1136/thoraxjnl-2012-201786. PMID 23321605. Archived from the original on 2021-08-28. Retrieved 2019-07-05.
- ↑ 61.0 61.1 Pulmonary Fibrosis Foundation. "Prevalence and Incidence". Pulmonaryfibrosis.org. Retrieved 2013-04-11
- ↑ Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ (2006). "Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK". Thorax. 61 (11): 980–985. doi:10.1136/thx.2006.062836. PMC 2121155. PMID 16844727.
- ↑ "Eurostat News Release. European demography. 110/2010. 27 July 2010" (PDF). Epp.eurostat.ec.europa.eu. Archived (PDF) from the original on 16 October 2013. Retrieved 7 June 2018.
- ↑ Hyldgaard C, Hilberg O, Muller A, Bendstrup E (2014). "A cohort study of interstitial lung diseases in central Denmark". Respiratory Medicine. 108 (5): 793–799. doi:10.1016/j.rmed.2013.09.002. PMID 24636811.
- ↑ Williams K, Malarkey D, Cohn L, Patrick D, Dye J, Toews G (2004). "Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect". Chest. 125 (6): 2278–2288. doi:10.1378/chest.125.6.2278. PMID 15189952.
- ↑ Webb JA, Armstrong J (2002). "Chronic idiopathic pulmonary fibrosis in a West Highland white terrier". The Canadian Veterinary Journal. 43 (9): 703–705. PMC 339552. PMID 12240528.
- ↑ "AKC Canine Health Foundation". Akcchf.org. Archived from the original on 12 June 2018. Retrieved 7 June 2018.
- ↑ "Active Clinical Trials and Investigational Research in IPF". Archived from the original on 2014-09-04. Retrieved 2014-09-04.
- ↑ "Research Demonstrates Reversal Of Pulmonary Fibrosis With miRagen Therapeutics Synthetic microRNA-29 Mimic (promiR-29)". Pulmonaryfibrosisnews.com. 2014-09-23. Archived from the original on 2015-04-01. Retrieved 8 June 2018.
- ↑ Liu M, Ren D, Wu D, Zheng J, Tu W (2015). "Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment". Current Stem Cell Research & Therapy. 10 (6): 466–76. doi:10.2174/1574888X10666150519092639. PMID 25986617.
- ↑ "Stem cell therapy for lung fibrosis conditions". Sciencedaily.com. Archived from the original on 12 June 2018. Retrieved 8 June 2018.
- Pages with script errors
- All articles lacking reliable references
- Articles lacking reliable references from June 2019
- Articles with invalid date parameter in template
- Articles with hAudio microformats
- Articles containing potentially dated statements from January 2016
- All articles containing potentially dated statements
- Articles with Curlie links
- Respiratory diseases principally affecting the interstitium
- Idiopathic diseases